Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Top Cited Papers
Open Access
- 4 May 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 389 (10086), 2287-2303
- https://doi.org/10.1016/s0140-6736(17)31191-1
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Mental health comorbidity in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- Guidelines for treatment of atopic eczema (atopic dermatitis) Part IIJournal of the European Academy of Dermatology and Venereology, 2012
- Guidelines for treatment of atopic eczema (atopic dermatitis) Part IJournal of the European Academy of Dermatology and Venereology, 2012
- EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important differenceAllergy, 2011
- Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trialJournal of the American Academy of Dermatology, 2011
- Percutaneous absorption of potent topical corticosteroids in patients with severe atopic dermatitisJournal of the American Academy of Dermatology, 2010
- Corticosteroid classes: A quick reference guide including patch test substances and cross-reactivityJournal of the American Academy of Dermatology, 2006
- The validity of the Hospital Anxiety and Depression ScaleJournal of Psychosomatic Research, 2002
- Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitisBritish Journal of Dermatology, 1997
- The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimensBritish Journal of Dermatology, 1996